Industry Focus Transcripts

Two Fools explain how to spot disruptive companies and a few caveats to keep in mind as you look.

Why Aetna is joining the ranks of commercial healthcare companies that are opting out of the Obamacare exchanges.

With the recently announced $4.5 billion deal between Cabela's and Bass Pro, the combined entity will employ 40,000 employees in 180 stores and feature millions of square footage of hunting, fishing, and camping equipment. We also take a look at Costco following its break-up with American Express.

Twilio is up over 150% from where it priced shares when it went public in June. There are a lot of reasons to like the cloud communication company, but can it keep growing fast enough to justify its valuation?

We continue our series on consumer and retail supertrends with a look at how two of the world’s largest conglomerates are working to reduce complexity within their businesses.

The Galaxy Note 7 line has officially been axed. What does it mean for Samsung, and who could benefit from the fallout?

Industry Focus looks at recently public Nutanix, explaining what it does and breaking down its business.

After over a year of speculation that the world's largest tech company was poised to become an auto manufacturer, Apple has reportedly backed off. Here's why.

After Puma Biotech's recent success, the search is on for other clinical-stage biotechs being run by proven CEOs. Could leadership experience turn Aurinia Pharmaceuticals, Axovant Sciences, and Esperion Therapeutics into winners too?

Small-cap stocks Novocure, Flexion Therapeutics, and Zogenix want to shake up healthcare, and investors are optimistic about their chances.

Chipotle is reporting earnings tonight -- here's what to expect, and what numbers you’ll want to pay attention to.

Renewable energy is taking off in some parts of the world, but it's far from replacing fossil fuels. And speaking of fossil fuels, the Industry Focus: Energy team checks in with OPEC, and some infrastructure and service players as well.

You might not be able to fire the coach or have a say in drafting new players, but there are ways to invest in professional sports.

With a slate of promising drugs hitting the market and in its development pipeline, Regeneron Pharmaceuticals is becoming one of biotechs most important players.

As company management faces off against an activist investor, shareholders will vote to determine if he should have a place on the board.

Next Monday’s solar eclipse will span across the U.S., and solar energy production will be surprisingly affected.

Everyone makes mistakes, but not many of us air them publicly. That's the theme of this week's "Industry Focus," starting with our prediction in 2015 that concerns about Wells Fargo's cross-selling culture were much ado about nothing.

Instead of investing in medical or recreational marijuana companies, it might make more sense to buy this back-door marijuana stock. Also, this could be the best precision medicine stock to buy, and it isn't even a drugmaker.

Investors are backing away from the Snapchat operator as more and more red flags appear.

Every diversified portfolio needs global exposure. We dive into some of the benefits and risks involved with international stocks.